Albert Jan van Hoek
Albert Jan van Hoek
Health economist / Infectious disease modeller, RIVM
Verified email at
Cited by
Cited by
Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study
S Flasche, AJ Van Hoek, E Sheasby, P Waight, N Andrews, C Sheppard, ...
PLoS Med 8 (4), e1001017, 2011
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
AJ van Hoek, N Andrews, PA Waight, J Stowe, P Gates, R George, ...
Journal of Infection 65 (1), 17-24, 2012
Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation
M Baguelin, AJ Van Hoek, M Jit, S Flasche, PJ White, WJ Edmunds
Vaccine 28 (12), 2370-2384, 2010
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
AJ van Hoek, CL Sheppard, NJ Andrews, PA Waight, MPE Slack, ...
Vaccine 32 (34), 4349-4355, 2014
The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy
D Cromer, AJ van Hoek, M Jit, WJ Edmunds, D Fleming, E Miller
Journal of Infection 68 (4), 363-371, 2014
Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales
AJ Van Hoek, N Gay, A Melegaro, W Opstelten, WJ Edmunds
Vaccine 27 (9), 1454-1467, 2009
Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 …
MH Rozenbaum, EAM Sanders, AJ van Hoek, AGSC Jansen, ...
Bmj 340, c2509, 2010
The early transmission dynamics of H1N1pdm influenza in the United Kingdom
A Ghani, M Baguelin, J Griffin, S Flasche, AJ van Hoek, S Cauchemez, ...
PLoS currents 1, 2009
Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes
AJ Van Hoek, N Andrews, PA Waight, R George, E Miller
PloS one 7 (7), e39150, 2012
Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England
AJ van Hoek, A Melegaro, E Zagheni, WJ Edmunds, N Gay
Vaccine 29 (13), 2411-2420, 2011
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
MH Rozenbaum, AJ van Hoek, D Fleming, CL Trotter, E Miller, ...
Bmj 345, e6879, 2012
Modelling the impact of local reactive school closures on critical care provision during an influenza pandemic
T House, M Baguelin, AJ Van Hoek, PJ White, Z Sadique, K Eames, ...
Proceedings of the Royal Society B: Biological Sciences 278 (1719), 2753-2760, 2011
The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom
AJ van Hoek, A Melegaro, N Gay, J Bilcke, WJ Edmunds
Vaccine 30 (6), 1225-1234, 2012
The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study
AJ Van Hoek, A Underwood, M Jit, E Miller, WJ Edmunds
PloS one 6 (3), e17030, 2011
The number of deaths among infants under one year of age in England with pertussis: results of a capture/ recapture analysis for the period 2001 to 2011
AJ van Hoek, H Campbell, G Amirthalingam, N Andrews, E Miller
Eurosurveillance 18 (09), 15-20, 2013
Cost–effectiveness of varicella vaccination programs: an update of the literature
MH Rozenbaum, AJ Van Hoek, S Vegter, MJ Postma, Chant, Rawson, ...
Expert review of vaccines 7 (6), 753-782, 2008
Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands
A van Lier, AJ van Hoek, W Opstelten, HJ Boot, HE de Melker
BMC health services research 10 (1), 237, 2010
Ebola virus disease in the Democratic Republic of the Congo, 1976-2014
A Rosello, M Mossoko, S Flasche, AJ Van Hoek, P Mbala, A Camacho, ...
Elife 4, e09015, 2015
Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
J Southern, N Andrews, P Sandu, CL Sheppard, PA Waight, NK Fry, ...
PLoS One 13 (5), e0195799, 2018
Cost-effectiveness of vaccinating immunocompetent≥ 65 year olds with the 13-valent pneumococcal conjugate vaccine in England
AJ van Hoek, E Miller
PLoS One 11 (2), e0149540, 2016
The system can't perform the operation now. Try again later.
Articles 1–20